I have a topic for discussion we can change to. How about
I have a topic for discussion we can change to. How about the Long Hauler study and the implications that it brings in helping the Long Haulers. Think about how big this group is internationally. Dr. K said that 75-87% of hospital admitted people become Long Haulers. This group is going to be huge going forward.
Also what it has brought forward in the knowledge that Leronlimab is reducing the brain fog of the LH group? They figured out that it is crossing the blood brain barrier. This is huge Finding. Dr. K said this brings forward the reason that Neurological diseases have benefit from Leronlimab and also wasn’t it mentioned that what Dr. Patterson has believed in the mechanism of action isn’t fully realized yet when it comes to positive immune modulation and the reason Leronlimab seems to work for so many indications. Not to limit it to Rantes only that positive immune Modulation isn’t fully understood yet.
We have so much information from that last interview we haven’t even touched on yet. When Nader says we have maybe the greatest immediate future of any company going forward. He is talking about these new findings and what they mean for us.
Yet we bicker over conspiracy theories instead of attacking the meat of our boards knowledge about the science of what we just found out. There is some great knowledge here on this board. There has been some real positive findings recently and we are missing the discussions we should be having.
How about we talk the science of Long Haulers?
How about we figure the market and value of the Long Haulers? Maybe they never get over Covid? I hope this can’t be true but what if... Maybe they are long term customers like HIV? We have a study and hopefully it has multiple doses to see if it can prevent the lingering effects of Covid for some time. What the real long term result will be is for how long?
So let’s hear some opinions on these resent developments and new information for a new direction for Covid patients. This is how we had this board performing in the past. The board has been diluted somewhat with new blood. But in that new blood is new opinions. Lets hear all opinions.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...
Continue Reading
A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...
Continue Reading
Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...
Continue Reading
A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...
Continue Reading
A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...
Continue Reading
Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....
Continue Reading
Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...
Continue Reading
Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...
Continue Reading
A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...
Continue Reading
Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...
Continue Reading
Top 5 Most Recently Viewed Articles
Empowering Future Educators with College Chapters In a progressive move to inspire and support the upcoming generation of teachers, the American Teachers Alliance (ATA) has launched a significant initiative aimed at engaging college students across universities. This initiative introduces college student chapters, fostering a community where aspiring educators can enhance...
Continue Reading
Introduction to Progress ShareFile's New Features Progress, a leading provider of AI-driven digital experience and infrastructure software, is excited to announce significant advancements to its ShareFile platform. The recent updates mark a transformative leap in how enterprises collaborate using Microsoft 365, empowering teams to work more securely and efficiently. Deep...
Continue Reading
Investigating Significant Mergers in 2025 In the financial landscape, the merging of companies can significantly impact shareholders. Recognizing the importance of every shareholder's voice, we delve into several notable mergers that are under scrutiny as we approach votes critical to shareholders. As many companies opt for merger routes, understanding the implications of...
Continue Reading
Unveiling the Daylight Shows at Daylight Studio Experience the vibrant world of creativity at Daylight Studio, a prominent event venue nestled in two of New York City's most dynamic areas, Hudson Yards and Flatiron. With years of experience in supporting film, fashion, and artistic endeavors, Daylight Studio has secured its place as a go-to location for creatives and...
Continue Reading
Ventyx Biosciences Begins Phase 2a Trial for VTX3232 Ventyx Biosciences, Inc. (Nasdaq: VTYX), a company focused on creating innovative oral treatments for various inflammatory diseases, has announced the start of dosing for its Phase 2a clinical trial of VTX3232. This important trial is centered on individuals who have been diagnosed with the early stages of Parkinson’s...
Continue Reading